Nasal eucoleosis in a symptomatic dog from Italy

Veronesi, Fabrizia; Lepri, Elvio; Morganti, Giulia; Palma, Stefano Di; Mechelli, Luca; Moretti, Annabella; Traversa, Donato

doi:10.1016/j.vetpar.2013.01.022

Cited by 28 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This dog received a second unsuccessful treatment for 2 weeks with fenbendazole (100 mg/kg BW per os) along with preventive measures, but the infection was not resolved until a final single administration of Advocate ® had been given (Alho et al 2016). The present data, along with other recent information (Veronesi et al 2013, 2014a, Alho et al 2016, confirm that moxidectin used in a spot-on formulation is a suitable choice for effective treatment and control of canine nasal capillariosis. Taking into account the potential direct life cycle of C. boehmi, further measures such as prompt removal of faeces from the environment and prevention of coprophagia or geophagic pica should be taken to prevent reinfection.…”

Section: Discussionsupporting

confidence: 84%

“…Taking into account the potential direct life cycle of C. boehmi, further measures such as prompt removal of faeces from the environment and prevention of coprophagia or geophagic pica should be taken to prevent reinfection. At the same time, post-treatment faecal examinations should also be performed to monitor the efficacy of the anthelmintic therapy and the occurrence of reinfection (Baan et al 2011, Veronesi et al 2013, Alho et al 2016). …”

Section: Discussionmentioning

confidence: 99%

“…Dogs infected by C. boehmi may be subclinically infected or show upper respiratory signs of varying severity, i.e. sneezing, reverse sneezing, hypo-or anosmia and catarrhal blood-stained or muco-purulent nasal discharge when bacterial infection occurs (Evinger et al 1985, Campbell and Little 1991, Piperisova et al 2010, Veronesi et al 2013. Meningoencephalitis and generalized convulsive seizures have been observed as a consequence of aberrant migration into the cranial cavity (Clark et al 2013).…”

Section: Introductionmentioning

confidence: 99%

“…In clinical settings the diagnosis relies on standard faecal flotations for detecting the typical eggs, which need to be differentiated from those of the lungworm Capillaria aerophila and of the best-known canine intestinal whipworm Trichuris vulpis (Di Cesare et al 2012). The detection of adult worms and eggs during rhinoscopic examination or cytologic evaluation of nasal flushing may also be used to diagnose the infection (Baan et al 2011, Veronesi et al 2013. Nevertheless, rhinoscopy is expensive, invasive, requires anaesthesia and is unsuitable when the parasite is located in the caudal portion of the nasal cavity or when abundant mucus is present (Veronesi et al 2014a).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate®, Advantage® Multi) in Comparison to an Untreated Control Group in the Treatment of Capillaria boehmi in Naturally Infected Dogs

Veronesi

Cesare

Braun³

et al. 2017

Parasitol Res

Self Cite

View full text Add to dashboard Cite

Capillaria boehmi affects the upper respiratory tract of domestic and wild canids. The aim of the present study was to investigate the efficacy of imidacloprid 10 % / moxidectin 2.5 % spot-on (Advocate ® , Advantage ® Multi, Bayer) in dogs naturally infected by C. boehmi. Twenty dogs infected with C. boehmi were randomly allocated to two groups: T1 (10 dogs) received a single treatment of Advocate ® using the recommended dose on day 0 and T2 (10 dogs) served as an untreated control group. The reduction of the faecal egg counts (EPG) from baseline (days -6 ± 2 and -2 ± 2) to study completion was set as the primary efficacy criterion; clinical assessments of the upper respiratory tract and a rhinoscopy to visualize the parasites were used as secondary efficacy criteria. Eight dogs in T1 were not shedding eggs on days 28 ± 2 (reduction of EPG 99.66 %). A second treatment was administered to two dogs still positive on days 30 ± 3. A second efficacy evaluation was performed on days 42 ± 2 (study completion), when the two dogs tested negative. The mean number of EPG at study completion was 0 in T1 and 368.49 in T2. The difference between the groups was statistically significant (P < 0.01). Treatment efficacy at study completion was 100 %. None of the T1 dogs showing clinical signs on day 0 were symptomatic on days 28 ± 2. No adverse events occurred. The results show that Advocate ® is safe and effective in the treatment of canine nasal capillariosis. Original Article S66EndoparasitEs

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate®, Advantage® Multi) in Comparison to an Untreated Control Group in the Treatment of Capillaria boehmi in Naturally Infected Dogs

Veronesi

Cesare

Braun³

et al. 2017

Parasitol Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Capillaria boehmi), which are mainly the parasitic nematodes of wild canids, e.g. foxes and wolves, but infections in domestic dogs have also been described (Magi et al, 2012;Macchioni et al, 2013;Veronesi et al, 2013). E. aerophilus may be responsible for rare zoonotic infections in humans (Aftandelians et al, 1977;Lalošević et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Cardiorespiratory and gastrointestinal parasites of dogs in north-west Italy

et al. 2016

View full text Add to dashboard Cite

SummaryThe present study was conducted to evaluate the prevalence of gastrointestinal and cardio-respiratory parasites in dogs in Liguria (northwest Italy) which is a region that has scarcely been studied. A total of 450 dogs (260 males and 190 females) were enrolled in the study from 2009 and 2013. All dogs lived in a rural or semi-rural environment in the provinces of Imperia (n = 352) or Savona (n = 98), Liguria. Coprological examinations showed that 197 dogs (43.8 %, CI 38.7-48.9 %) were infected by parasites. Specifi cally, 3.3 % of the dogs presented only cardio-respiratory species, 32.4 % only intestinal species, and 8.0 % presented a mixed infection. The most frequent intestinal parasites were Toxocara canis (20 %), Trichuris vulpis (17.8 %), Ancylostomatidae (12 %), Coccidia (2.7 %), Aonchotheca putorii (1.8 %) and Toxascaris leonina (1.8 %). The cardio-respiratory species found were Eucoleus aerophilus (9.6 %), Eucoleus boehmi (1.6 %), Angiostrongylus vasorum (0.7 %), and Crenosoma vulpis (0.2 %). A total of 116 dogs (25.8 %) were parasitized by a single species, multiple infections were observed in 81 dogs (18.0 %) up to a six-order infection. This preliminary study highlighted that the prevalence of intestinal parasites in investigated area is high. Cardio respiratory parasites were detected in an area that has not been investigated before. The creation of a more extensive sampling programme of the area, on a provincial basis in order to build a more detailed map of prevalences for different species of dog parasites throughout Liguria, a more extensive sampling programme of the area needs to be created -ideally for each province.

show abstract

Sneezing and Coughing

2019

Common Clinical Presentations in Dogs and Cats

View full text Add to dashboard Cite

Nasal eucoleosis in a symptomatic dog from Italy

Cited by 28 publications

References 12 publications

Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate®, Advantage® Multi) in Comparison to an Untreated Control Group in the Treatment of Capillaria boehmi in Naturally Infected Dogs

Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate®, Advantage® Multi) in Comparison to an Untreated Control Group in the Treatment of Capillaria boehmi in Naturally Infected Dogs

Cardiorespiratory and gastrointestinal parasites of dogs in north-west Italy

Sneezing and Coughing

Contact Info

Product

Resources

About